Advances in metformin for the treatment of non-alcoholic fatty liver disease in children

References

• Rinella ME. Non-alcoholic fatty liver disease: a systematic review. Jama. 2015 Jun 9;313(22):2263–2273. PubMed PMID: 26057287; eng.
   PubMed Web of Science ®Google Scholar
• Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013Apr;27(2):195–208. PubMed PMID: 23731881; eng.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Curtin LR, et al. prevalence of high body mass index in US children and adolescents, 2007-2008. Jama. 2010 Jan 20;303(3):242–249. PubMed PMID: 20071470; eng.
   PubMed Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Clin Pract Gastroenterol Hepatol. 2013Nov;10(11):686–690. PubMed PMID: 24042449; eng.
   Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018Jan;671:328–357. PubMed PMID: 28714183; eng
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md). Hepatology (Baltimore, Md.). 2016Jul;641:73–84. PubMed PMID: 26707365; eng
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Newton KP, et al. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016Jun;150:1798–1810. PubMed PMID: 27003600; PubMed Central PMCID: PMCPMC4887388. eng
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019Mar;70(3):531–544. PubMed PMID: 30414863; eng.
   PubMed Web of Science ®Google Scholar
• Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PloS one. 2015;10(10):e0140908. PubMed PMID: 26512983; PubMed Central PMCID: PMCPMC4626023. eng.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu M, Liu Z, et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ open. 2021 May 4;11(5):e042843. PubMed PMID: 33947727; PubMed Central PMCID: PMCPMC8098935. eng.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md). Hepatology (Baltimore, Md.). 2015May;615:1547–1554. PubMed PMID: 25125077; eng
   PubMed Web of Science ®Google Scholar
• Pacifico L, Nobili V, Anania C, et al. Pediatric non-alcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011 Jul 14;17(26):3082–3091. PubMed PMID: 21912450; PubMed Central PMCID: PMCPMC3158407. eng.
   PubMed Web of Science ®Google Scholar
• Pacifico L, Chiesa C, Anania C, et al. Non-alcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol. 2014 Jul 21;20(27):9055–9071. PubMed PMID: 25083079; PubMed Central PMCID: PMCPMC4112863. eng.
   PubMed Web of Science ®Google Scholar
• Pacifico L, Bonci E, Andreoli GM, et al. The impact of nonalcoholic fatty liver disease on renal function in children with overweight/obesity. Int J Mol Sci. 2016 Jul 27;17(8):1218. PubMed PMID: 27472326; PubMed Central PMCID: PMCPMC5000616. eng.
   Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Clin Pract Gastroenterol Hepatol. 2021Apr;18(4):223–238. PubMed PMID: 33349658; PubMed Central PMCID: PMCPMC8016738. eng.
   Google Scholar
• Garuti F, Neri A, Avanzato F, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021Mar;413:585–597. PubMed PMID: 33219585; eng
   PubMed Web of Science ®Google Scholar
• El Aziz MA A, Facciorusso A, Nayfeh T, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines (Basel). 2020 Oct 19;8(4). PubMed PMID: 33086471; PubMed Central PMCID: PMCPMC7712941. eng.
   Web of Science ®Google Scholar
• Facciorusso A, El Aziz MA A, Sacco R. Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. Cancers (Basel). 2019 Dec 20;12(1):36. PubMed PMID: 31877664; PubMed Central PMCID: PMCPMC7017079. eng.
   Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Singh S, et al. Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis. Cancers (Basel). 2020 Apr 3;12(4):874. PubMed PMID: 32260179; PubMed Central PMCID: PMCPMC7225931. eng.
   Web of Science ®Google Scholar
• Fang YL, Chen H, Wang CL, et al. pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory” to “multiple hit model.” World J Gastroenterol. 2018 Jul 21;24(27):2974–2983. PubMed PMID: 30038464; PubMed Central PMCID: PMCPMC6054950. eng.
   PubMed Web of Science ®Google Scholar
• Vairetti M, Di Pasqua LG, Cagna M, et al. Changes in glutathione content in liver diseases: an update. antioxidants (Basel, Switzerland). Antioxidants (Basel, Switzerland). 2021 Feb 28;10(3). PubMed PMID: 33670839; PubMed Central PMCID: PMCPMC7997318. eng.
   PubMedGoogle Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860–867. PubMed PMID: 17167474; eng.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim SG. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. Clin Mol Hepatol. 2020Oct;26(4):715–727. PubMed PMID: 32951410; PubMed Central PMCID: PMCPMC7641579. eng.
   PubMed Web of Science ®Google Scholar
• Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cellular and molecular life sciences. Cmls. 2019Apr;76(8):1541–1558. PubMed PMID: 30683985; eng.
   PubMed Web of Science ®Google Scholar
• Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018Oct;6710:1881–1891. PubMed PMID: 28774887; eng
   PubMed Web of Science ®Google Scholar
• Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr. 2022Jan;76(1):28–39. PubMed PMID: 34006994; eng.
   PubMed Web of Science ®Google Scholar
• Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. PubMed PMID: 22281838; eng. 2012Mar;55(3):661–663. Hepatology (Baltimore, Md)
   Google Scholar
• Yan C, Tian X, Li J, et al. A high-fat diet attenuates AMPK α1 in adipocytes to induce exosome shedding and non-alcoholic fatty liver development in vivo. Diabetes. 2021Feb;70:577–588. PubMed PMID: 33262120; PubMed Central PMCID: PMCPMC7881856. eng
   PubMed Web of Science ®Google Scholar
• Zhang Z, Thorne JL, Moore JB. Vitamin D and non-alcoholic fatty liver disease. Current opinion in clinical nutrition and metabolic care. Current Opinion in Clinical Nutrition and Metabolic Care. 2019Nov;22(6):449–458. PubMed PMID: 31589177; eng.
   PubMed Web of Science ®Google Scholar
• Medrano M, Arenaza L, Migueles JH, et al. Associations of physical activity and fitness with hepatic steatosis, liver enzymes, and insulin resistance in children with overweight/obesity. Pediatr Diabetes. 2020Jun;214:565–574. PubMed PMID: 32237015; eng
   PubMed Web of Science ®Google Scholar
• Karaivazoglou K, Kalogeropoulou M, Assimakopoulos S, et al. Psychosocial issues in pediatric nonalcoholic fatty liver disease. Psychosomatics. 2019Jan-Feb;60:10–17. PubMed PMID: 30318268; eng
   PubMed Web of Science ®Google Scholar
• Orkin S, Brokamp C, Yodoshi T, et al. Community socioeconomic deprivation and nonalcoholic fatty liver disease severity. J Pediatr Gastroenterol Nutr. 2020Mar;70:364–370. PubMed PMID: 31651666; PubMed Central PMCID: PMCPMC8054652. eng
   PubMed Web of Science ®Google Scholar
• Trovato FM, Martines GF, Brischetto D, et al. Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion. Liver Int. 2016Mar;363:427–433. PubMed PMID: 26346413; eng
   PubMed Web of Science ®Google Scholar
• Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci. 2010 Jun 8;119(6):239–250. PubMed PMID: 20415664; eng. London, England: 1979.
   Web of Science ®Google Scholar
• Huang Y, Fu JF, Shi HB, et al. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes. Zhonghua Er Ke Za Zhi. 2011Feb; 492: 139–145 PubMed PMID: 21426695; chi
   PubMedGoogle Scholar
• Caton PW, Nayuni NK, Kieswich J, et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010Apr;2051:97–106. PubMed PMID: 20093281; eng
   PubMed Web of Science ®Google Scholar
• Abderrahmani A, Yengo L, Caiazzo R, et al. Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity-associated type 2 diabetes. Diabetes. 2018Jul;677:1310–1321. PubMed PMID: 29728363; eng
   PubMed Web of Science ®Google Scholar
• Han MS, Park SY, Shinzawa K, et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res. 2008Jan;491:84–97. PubMed PMID: 17951222; eng
   PubMed Web of Science ®Google Scholar
• Song YM, Lee YH, Kim JW, et al. metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. 2015;11(1):46–59. PubMed PMID: 25484077; PubMed Central PMCID: PMCPMC4502778. eng.
   PubMed Web of Science ®Google Scholar
• Zhang D, Ma Y, Liu J, et al. Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor eb-dependent autophagy. Front Pharmacol. 2021;12:689111. PubMed PMID: 34366846; PubMed Central PMCID: PMCPMC8346235. eng
   PubMed Web of Science ®Google Scholar
• El-Din SH S, Salem MB, El-Lakkany NM, et al. Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol. 2021Sep;40:1496–1509. PubMed PMID: 33678036; eng
   PubMed Web of Science ®Google Scholar
• Hubbard PA, Moody CL, Murali R. Allosteric modulation of ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol. 2014;5:478. PubMed PMID: 25566081; PubMed Central PMCID: PMCPMC4267178. eng.
   PubMed Web of Science ®Google Scholar
• Cameron AR, Morrison VL, Levin D, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016 Aug 19;119(5):652–665. PubMed PMID: 27418629; PubMed Central PMCID: PMCPMC4990459. eng.
   PubMed Web of Science ®Google Scholar
• Brandt A, Hernández-Arriaga A, Kehm R, et al. metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci Rep. 2019 Apr 30;9(1):6668. PubMed PMID: 31040374; PubMed Central PMCID: PMCPMC6491483 project. All other authors declare no competing interests. eng.
   PubMedGoogle Scholar
• Vasamsetti SB, Karnewar S, Kanugula AK, et al. metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015Jun;646:2028–2041. PubMed PMID: 25552600; eng
   PubMed Web of Science ®Google Scholar
• de Souza Teixeira Aa, Souza CO, Biondo LA, et al. Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. Inflammopharmacology. 2018Aug;264:1103–1115. PubMed PMID: 29450671; eng
   PubMed Web of Science ®Google Scholar
• Woo SL, Xu H, Li H, et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PloS one. 2014;9(3):e91111. PubMed PMID: 24638078; PubMed Central PMCID: PMCPMC3956460. eng.
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179–185. PubMed PMID: 22297845; PubMed Central PMCID: PMCPMC3276682. eng.
   PubMed Web of Science ®Google Scholar
• Yasmin T, Rahman MM, Khan F, et al. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways. Biochem Biophys Rep. 2021 Dec;28:101168. PubMed PMID: 34825068; PubMed Central PMCID: PMCPMC8605070. eng
   PubMedGoogle Scholar
• El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000 Jan 7;275(1):223–228. PubMed PMID: 10617608; eng.
   PubMed Web of Science ®Google Scholar
• Stachowicz A, Suski M, Olszanecki R, et al. Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. J Proteomics. 2012 Dec 21;77:167–175. PubMed PMID: 22960565; eng.
   PubMed Web of Science ®Google Scholar
• Kim DS, Jeong SK, Kim HR, et al. metformin regulates palmitate-induced apoptosis and ER stress response in Hepg2 liver cells. Immunopharmacol Immunotoxicol. 2010Jun;322:251–257. PubMed PMID: 20038265; eng
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262–266. PubMed PMID: 26633628; PubMed Central PMCID: PMCPMC4681099. eng.
   PubMed Web of Science ®Google Scholar
• Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020Feb;5787795:444–448. PubMed PMID: 31875646; PubMed Central PMCID: PMCPMC7234839. eng
   PubMed Web of Science ®Google Scholar
• Rezvanian H, Hashemipour M, Kelishadi R, et al. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr. 2010Nov;64:317–322. PubMed PMID: 21080144; eng
   PubMed Web of Science ®Google Scholar
• Zhu X, Yan H, Xia M, et al. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. Lipids Health Dis. 2018 May 14;17(1):114. PubMed PMID: 29759071; PubMed Central PMCID: PMCPMC5952420. eng.
   PubMedGoogle Scholar
• Ma M, Duan R, Shen L, et al. The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice. J Lipid Res. 2020Jul;617:1052–1064. PubMed PMID: 32229588; PubMed Central PMCID: PMCPMC7328049. eng
   PubMed Web of Science ®Google Scholar
• Huang H, Lee SH, Sousa-Lima I, et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018 Dec 3;128(12):5335–5350. PubMed PMID: 30226474; PubMed Central PMCID: PMCPMC6264719. eng.
   PubMed Web of Science ®Google Scholar
• Geerling JJ, Boon MR, van der Zon GC, et al. metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014Mar;633:880–891. PubMed PMID: 24270984; eng
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Middleton MS, Deutsch R, et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005 Apr 1;21(7):871–879. PubMed PMID: 15801922; eng.
   PubMed Web of Science ®Google Scholar
• Kendall D, Vail A, Amin R, et al. metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013Jan;981:322–329. PubMed PMID: 23175691; eng
   PubMed Web of Science ®Google Scholar
• Shargorodsky M, Omelchenko E, Matas Z, et al. Relation between augmentation index and adiponectin during one-year metformin treatment for non-alcoholic steatohepatosis: effects beyond glucose lowering? Cardiovascular diabetology. Cardiovascular Diabetology. 2012 Jun 7;11:61. PubMed PMID: 22676459; PubMed Central PMCID: PMCPMC3471007. eng.
   PubMed Web of Science ®Google Scholar
• Hookman P, Barkin JS. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol. 2003Feb;98(2):495–499. PubMed PMID: 12591075; eng.
   PubMedGoogle Scholar
• Karise I, Ornellas F, Barbosa-da-Silva S, et al. Liver and metformin: lessons of a fructose diet in mice. Biochim Open. 2017 Jun;4:19–30. PubMed PMID: 29450137; PubMed Central PMCID: PMCPMC5801827. eng.
   PubMedGoogle Scholar
• Liu F, Wang C, Zhang L, et al. metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. Int J Mol Med. 2014Jan;331:51–58. PubMed PMID: 24253218; PubMed Central PMCID: PMCPMC3868560. eng
   PubMed Web of Science ®Google Scholar
• Chen T, Yan D, Cheng X, et al. miR-1224-5p enhances hepatic lipogenesis by targeting adenosine monophosphate-activated protein kinase α1 in male mice. Endocrinology. 2018 May 1;159(5):2008–2021. PubMed PMID: 29474539; eng.
   PubMed Web of Science ®Google Scholar
• Han Y, Hu Z, Cui A, et al. Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nat Commun. 2019 Feb 7;10(1):623. PubMed PMID: 30733434; PubMed Central PMCID: PMCPMC6367348. eng.
   PubMedGoogle Scholar
• Szuster-Ciesielska A, Zwolak A, Daniluk J, et al. metformin inhibits both oleic acid-induced and CB1R receptor agonist-induced lipid accumulation in Hep3B cells: the preliminary report. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419832714. PubMed PMID: 30880507; PubMed Central PMCID: PMCPMC6423672. eng.
   Web of Science ®Google Scholar
• Kita Y, Takamura T, Misu H, et al. metformin prevents and reverses inflammation in a non-diabetic mouse model of non-alcoholic steatohepatitis. PloS One. 2012;7(9):e43056. PubMed PMID: 23028442; PubMed Central PMCID: PMCPMC3445596 Sumitomo Pharma, which deals in metformin. Dainippon Sumitomo Pharma supported the study by materials but has no role in the study design and has no financial interest of the results. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. eng.
   PubMed Web of Science ®Google Scholar
• Katsura A, Morishita A, Iwama H, et al. MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis. Int J Mol Med. 2015Apr;354:877–884. PubMed PMID: 25672270; PubMed Central PMCID: PMCPMC4356452. eng
   PubMed Web of Science ®Google Scholar
• Nguyen G, Park SY, Le CT, et al. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. Biochem Biophys Res Commun. 2018 Jan 22;495(4):2649–2656. PubMed PMID: 29278707; eng.
   PubMed Web of Science ®Google Scholar
• Luo T, Nocon A, Fry J, et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes. 2016Aug;658:2295–2310. PubMed PMID: 27207538; PubMed Central PMCID: PMCPMC4955985. eng
   PubMed Web of Science ®Google Scholar
• Ma T, Tian X, Zhang B, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 2022Mar;6037899:159–165. PubMed PMID: 35197629; PubMed Central PMCID: PMCPMC8891018. eng
   PubMed Web of Science ®Google Scholar
• Rabanal-Ruiz Y, Otten EG, KorolchuksVI, et al. mTORC1 as the main gateway to autophagy. Essays Biochem. 2017 Dec 12;61(6):565–584. PubMed PMID: 29233869; PubMed Central PMCID: PMCPMC5869864. eng.
   PubMed Web of Science ®Google Scholar
• Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017 Apr 20;36(16):2191–2201. PubMed PMID: 27748764; PubMed Central PMCID: PMCPMC5393956. eng.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol. 2005May;100:1082–1090. PubMed PMID: 15842582; eng
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853–860. PubMed PMID: 19811343; eng
   PubMed Web of Science ®Google Scholar
• Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol. 2009May;23:1082–1090. PubMed PMID: 21180541; PubMed Central PMCID: PMCPMC3002518. eng
   Google Scholar
• Dujic T, Zhou K, Donnelly LA, et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015May;645:1786–1793. PubMed PMID: 25510240; PubMed Central PMCID: PMCPMC4452716. eng
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992Apr;105(4):1009–1013. PubMed PMID: 1504710; PubMed Central PMCID: PMCPMC1908709. eng.
   PubMed Web of Science ®Google Scholar
• Yi F, Sun J, Lim GE, et al. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008May;1495:2341–2351. PubMed PMID: 18258680; eng
   PubMed Web of Science ®Google Scholar
• Hameed M, Khan K, Salman S, et al. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J Ayub Medical College Abbottabad. 2017Apr-Jun; 292: 225–229 PubMed PMID: 28718236; eng
   PubMedGoogle Scholar
• van der Molen Aj, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR contrast medium safety committee guidelines. Eur Radiol. 2018Jul;287:2856–2869. PubMed PMID: 29417249; PubMed Central PMCID: PMCPMC5986837. eng
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric non-alcoholic fatty liver disease. Hepatology (Baltimore, Md). Hepatology (Baltimore, Md.). 2012Apr;55(4):1292–1295. PubMed PMID: 22461076; PubMed Central PMCID: PMCPMC3325147. eng.
   PubMedGoogle Scholar
• Said A, Akhter A. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol. 2017Jul-Aug;16(4):538–547. PubMed PMID: 28611274; eng.
   PubMed Web of Science ®Google Scholar
• Nádasdi Á, Somogyi A,Igaz P, et al. EASL-EASD-easo clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016Jun; 64(6):1388–1402. PubMed PMID: 27062661; eng.
   PubMed Web of Science ®Google Scholar
• Bruckbauer A, Banerjee J, Fu L, et al. A combination of leucine, metformin, and sildenafil treats nonalcoholic fatty liver disease and steatohepatitis in mice. Int J Hepatol. 2016;2016:9185987. PubMed PMID: 28042486; PubMed Central PMCID: PMCPMC5155097 stockholders of NuSirt Biopharma Inc. Antje Bruckbauer and Michael B. Zemel also have patents related to the reported work. All other authors have declared that no competing interests exist. eng.
   PubMedGoogle Scholar
• Shin NR, Bose S, Wang JH, et al. flos lonicera combined with metformin ameliorates hepatosteatosis and glucose intolerance in association with gut microbiota modulation. frontiers in microbiology. Frontiers in Microbiology. 2017;8:2271. PubMed PMID: 29204141; PubMed Central PMCID: PMCPMC5698303. eng
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297–2307. PubMed PMID: 17135584; eng.
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016 Sep 6;165(5):305–315. PubMed PMID: 27322798; eng.
   PubMed Web of Science ®Google Scholar
• Williams CD, Stengel J, Asike MI, et al. prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011Jan;140:124–131. PubMed PMID: 20858492; eng
   PubMed Web of Science ®Google Scholar
• Wang C, Niederstrasser H, Douglas PM, et al. Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun. 2017 Dec 22;8(1):2270. PubMed PMID: 29273768; PubMed Central PMCID: PMCPMC5741634. eng.
   PubMedGoogle Scholar
• Harrison SA, Alkhouri N, Davison BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020Apr;724:613–626. PubMed PMID: 31697972; eng
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet ( London, England). 2016 Feb 13;387(10019):679–690. PubMed PMID: 26608256; eng.
   PubMed Web of Science ®Google Scholar
• Sato K, Gosho M, Yamamoto T, et al. Vitamin E has a beneficial effect on non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015Jul-Aug;317–8:923–930. PubMed PMID: 26059365; eng
   PubMed Web of Science ®Google Scholar
• Xu R, Tao A, Zhang S, et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–3934. PubMed PMID: 26064294; PubMed Central PMCID: PMCPMC4443128. eng.
   PubMed Web of Science ®Google Scholar
• Miller ERs3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005 Jan 4;142(1):37–46. PubMed PMID: 15537682; eng.
   PubMed Web of Science ®Google Scholar
• Abner EL, Schmitt FA, Mendiondo MS, et al. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011Jul;42:158–170. PubMed PMID: 21235492; PubMed Central PMCID: PMCPMC4030744. eng
   PubMedGoogle Scholar
• Olbers T, Gronowitz E, Werling M, et al. Two-year outcome of laparoscopic roux-en-y gastric bypass in adolescents with severe obesity: results from a Swedish nationwide study (AMOS).Int J Obesity. 2012 Nov;36(11):1388–1395. PubMed PMID: 23007037; eng. (2005).
   Web of Science ®Google Scholar
• Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013May;63:395–402. PubMed PMID: 23508758; eng
   PubMed Web of Science ®Google Scholar
• Coyle C, Cafferty FH, Vale C, et al. metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. PubMed PMID: 27681864; PubMed Central PMCID: PMCPMC5178140. eng, Ann Oncol. 2016 Dec;27(12):2184–2195.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with non-alcoholic fatty liver disease: a randomized, controlled trial. Hepatology (Baltimore, Md). Hepatology (Baltimore, Md.). 2008Jul;481:119–128. PubMed PMID: 18537181; eng
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. Jama. 2019 Jan 22;321(3):256–265. PubMed PMID: 30667502; PubMed Central PMCID: PMCPMC6440226; eng.
   PubMed Web of Science ®Google Scholar
• Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce non-alcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014 Nov;260(5):1496–1509. discussion 898-9.
   Web of Science ®Google Scholar
• Jan A, Narwaria M, Mahawar KK. A systematic review of bariatric surgery in patients with liver cirrhosis. Obes Surg. 2015Aug;25(8):1518–1526. PubMed PMID: 25982807; eng.
   PubMed Web of Science ®Google Scholar
• Pham YH, Miloh T. Liver transplantation in children. Clinics in Liver Disease. 2018Nov;22(4):807–821. PubMed PMID: 30266163; eng.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020Jul;731:26–39. PubMed PMID: 32147362; eng
   PubMed Web of Science ®Google Scholar